Ovarian Neoplasms

"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Descriptor ID	D010051
MeSH Number(s)	C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
Concept/Terms	Ovarian Neoplasms Ovarian Neoplasms Neoplasm, Ovarian Ovarian Neoplasm Ovary Neoplasms Neoplasm, Ovary Neoplasms, Ovary Ovary Neoplasm Neoplasms, Ovarian Ovary Cancer Ovary Cancer Cancer, Ovary Cancers, Ovary Ovary Cancers Ovarian Cancer Cancer, Ovarian Cancers, Ovarian Ovarian Cancers Cancer of Ovary Cancer of the Ovary

Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Endocrine Gland Neoplasms [C04.588.322]
Ovarian Neoplasms [C04.588.322.455]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Genital Diseases, Female [C13.351.500]
Adnexal Diseases [C13.351.500.056]
Ovarian Diseases [C13.351.500.056.630]
Ovarian Neoplasms [C13.351.500.056.630.705]
Urogenital Neoplasms [C13.351.937]
Genital Neoplasms, Female [C13.351.937.418]
Ovarian Neoplasms [C13.351.937.418.685]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Ovarian Neoplasms [C19.344.410]
Gonadal Disorders [C19.391]
Ovarian Diseases [C19.391.630]
Ovarian Neoplasms [C19.391.630.705]

Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".

Ovarian Neoplasms
Granulosa Cell Tumor
Hereditary Breast and Ovarian Cancer Syndrome
Luteoma
Meigs Syndrome
Sertoli-Leydig Cell Tumor
Thecoma

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.

Bar chart showing 262 publications over 26 distinct years, with a maximum of 30 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
1998	0	1	1
2001	0	1	1
2002	7	3	10
2003	4	0	4
2004	2	2	4
2005	2	2	4
2006	4	1	5
2007	11	0	11
2008	12	0	12
2009	10	0	10
2010	16	2	18
2011	16	1	17
2012	12	2	14
2013	18	0	18
2014	20	1	21
2015	28	2	30
2016	12	1	13
2017	12	0	12
2018	9	0	9
2019	12	0	12
2020	8	1	9
2021	4	0	4
2022	8	0	8
2023	10	0	10
2024	3	0	3

Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.

Carey KM, Young CD, Clark AJ, Dammer EB, Singh R, Lillard JW. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment. J Ovarian Res. 2024 Dec 03; 17(1):240.

View in: PubMed
Nelson BH, Hamilton P, Phung MT, Milne K, Harris B, Thornton S, Stevens D, Kalaria S, Singh K, Laumont CM, Moss E, Alimujiang A, Meagher NS, Bolithon A, Fereday S, Kennedy CJ, Hendley J, Ariyaratne D, Alsop K, Traficante N, Goode EL, Karnezis A, Shen H, Richardson J, McKinnonDeurloo C, Chase A, Grout B, Doherty JA, Harris HR, Cushing-Haugen KL, Anglesio M, Heinze K, Huntsman D, Talhouk A, Hanley GE, Alsop J, Jimenez-Linan M, Pharoah PD, Boros J, Brand AH, Harnett PR, Sharma R, Hecht JL, Sasamoto N, Terry KL, Karlan B, Lester J, Carney ME, Goodman MT, Hernandez BY, Wilkens LR, Behrens S, Turzanski Fortner R, Fasching PA, Bisinotto C, Candido Dos Reis FJ, Ghatage P, K?bel M, Elishaev E, Modugno F, Cook L, Le N, Gentry-Maharaj A, Menon U, Garc?a MJ, Rodriguez-Antona C, Farrington K, Kelemen LE, Kommoss S, Staebler A, Garsed DW, Brenton JD, Piskorz AM, Bowtell DD, DeFazio A, Ramus SJ, Pike MC, Pearce CL. Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. J Clin Invest. 2024 Oct 29; 134(24).

View in: PubMed
Kaur P, Singh SK, Mishra MK, Singh S, Singh R. Nanotechnology for boosting ovarian cancer immunotherapy. J Ovarian Res. 2024 Oct 14; 17(1):202.

View in: PubMed
Cruz LS, Robinson M, Stevenson D, Amador IC, Jordan GJ, Valencia S, Navarrete C, House CD. Chemotherapy Enriches for Proinflammatory Macrophage Phenotypes that Support Cancer Stem-Like Cells and Disease Progression in Ovarian Cancer. Cancer Res Commun. 2024 Oct 01; 4(10):2638-2652.

View in: PubMed
Meagher NS, White KK, Wilkens LR, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cushing-Haugen KL, Jordan S, Kaufmann SH, Le ND, Pike MC, Riggan M, Qin B, Rothstein JH, Titus L, Winham SJ, Anton-Culver H, Doherty JA, Goode EL, Pearce CL, Risch HA, Webb PM, Cook LS, Goodman MT, Harris HR, Le Marchand L, McGuire V, Pharoah PDP, Sarink D, Schildkraut JM, Sieh W, Terry KL, Thompson PJ, Whittemore AS, Wu AH, Peres LC, Merritt MA. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. Am J Epidemiol. 2024 Sep 03; 193(9):1242-1252.

View in: PubMed
LeBien J, Velev J, Roche-Lima A. Indirect reference interval estimation using a convolutional neural network with application to cancer antigen 125. Sci Rep. 2024 08 20; 14(1):19332.

View in: PubMed
Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N, Alsop K, Christie EL, Kang EY, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Alsop J, Beckmann MW, Boros J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen KL, Cybulski C, El-Bahrawy MA, Elishaev E, Erber R, Gayther SA, Gentry-Maharaj A, Gilks CB, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Jakubowska A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Kluz T, Koziak JM, Kristjansdottir B, Le ND, Lener M, Lester J, Lubinski J, Mateoiu C, Orsulic S, Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Soong TR, Steed H, Sukumvanich P, Talhouk A, Taylor SE, Vierkant RA, Wang C, Widschwendter M, Wilkens LR, Winham SJ, Anglesio MS, Berchuck A, Brenton JD, Campbell I, Cook LS, Doherty JA, Fasching PA, Fortner RT, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sundfeldt K, Swerdlow AJ, Goode EL, DeFazio A, K?bel M, Ramus SJ, Bowtell DDL, Garsed DW. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma. Clin Cancer Res. 2024 Aug 15; 30(16):3481-3498.

View in: PubMed
Tecchio KB, Alves FM, Alves JD, Barbosa CS, Salgado MAR, Santos VJDSVD, Varotti FP, Campos-Junior PHA, Viana GHR, Santos FVD. Evaluation of the in vivo acute toxicity and in vitro genotoxicity and mutagenicity of synthetic ?-carboline alkaloids with selective cytotoxic activity against ovarian and breast cancer cell lines. Mutat Res Genet Toxicol Environ Mutagen. 2024 Oct; 899:503808.

View in: PubMed
Waters JA, Robinson M, Lujano-Olazaba O, Lucht C, Gilbert SF, House CD. Omental Preadipocytes Stimulate Matrix Remodeling and IGF Signaling to Support Ovarian Cancer Metastasis. Cancer Res. 2024 Jul 02; 84(13):2073-2089.

View in: PubMed
Hanafi D, Onyenwoke RU, Kimbro KS. The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines. Int J Mol Sci. 2024 Jun 13; 25(12).

View in: PubMed

People

Explore

Similar Concepts

Top Journals